Form 4: ALX Oncology Director Granted 40,400 Stock Options

ALX Oncology Holdings Inc. Director J. Scott Garland was granted 40,400 stock options with an exercise price of $1.32, vesting monthly starting February 20, 2026.

Summary

• J. Scott Garland, a Director of ALX Oncology Holdings Inc. (ALXO), acquired 40,400 stock options.
• The transaction date for this acquisition was January 20, 2026.
• Each stock option has an exercise price of $1.32.
• The options will vest in 12 equal monthly installments, commencing on February 20, 2026.
• The expiration date for these stock options is January 19, 2036.
• Following this transaction, J. Scott Garland directly beneficially owns 40,400 derivative securities.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates continued alignment of a director's interests with shareholders through equity compensation, which is a standard practice.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The exercise price of $1.32 provides a clear benchmark for future stock performance required for the options to be in-the-money.

Negatives

• No direct negatives are apparent from this routine insider transaction filing.

Risks

• The value of the stock options is subject to the future market price of ALX Oncology Holdings Inc. common stock, which may fluctuate.
• If the stock price does not exceed the exercise price of $1.32, the options may expire worthless.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's operational or financial performance, focusing solely on an insider's equity transaction.

Industry Context

Insider transactions, such as stock option grants, are a common form of executive and director compensation in the biotechnology and pharmaceutical industries. They are designed to align the interests of company leadership with shareholder value creation, particularly in growth-oriented sectors like oncology where long-term development cycles are prevalent.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's financial incentives with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The stock options will vest in 12 equal monthly installments beginning February 20, 2026.
• The director may choose to exercise the vested options at any time before the expiration date of January 19, 2036, subject to company policy and blackout periods.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their compensation. While it signals continued alignment of interests, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should consider this as a standard governance event rather than a catalyst for a buy or sell decision.

Keywords

ALX Oncology, ALXO, stock options, insider transaction, Form 4, director compensation, equity grant, beneficial ownership